Early national data suggest that Medicare’s expanded clinical indications for reimbursement were warranted
Preliminary results from the National Oncologic PET Registry indicate that FDG-PET led referring physicians to alter the clinical management for more than one-third of nearly 23,000 cancer patients who underwent the procedures.
The NOPR was devised to confirm that FDG-PET is as efficacious in clinical practice as it appeared to be in clinical trials. Those trials preceded the decision of the Centers for Medicare and Medicaid Services in 2005 to conditionally grant reimbursement for most applications for cancer diagnosis, staging, and treatment monitoring. The requirement for a registry, to be managed by the American College of Radiology Imaging Network, was included in Medicare’s coverage determination in order to measure FDG-PET’s influence on clinical decision making.
The first year of data compiled by the NOPR suggest that using FDG-PET as a cancer imaging tool for all types of malignancies makes sense, said coauthor Dr. Barry A. Siegel, director of nuclear medicine at the Mallinckrodt Institute of Radiology and cochair of the NOPR working group.
“Medicare should, when given the opportunity to look at these data formally, strongly consider opening up the coverage to include either all cancers or most cancers,” he said.
Siegel was part of a team of eight investigators who gathered the data under the lead of Dr. Bruce E. Hillner, associate chair of internal medicine at Virginia Commonwealth University. They reviewed 22,975 cases entered in the registry from May 8, 2006, to May 7, 2007. The most common cancer types in the registry affected the prostate, ovary and uterine adnexa, pancreas, and bladder.
On average, physicians changed their management in 36% of cases based on PET results. For 28% of the cases, FDG-PET led the referring physician to shift from nontreatment to treatment. For 8%, the imaging results led the physician to decide against treatment.
Researchers expressed satisfaction that NOPR results are consistent with prior published literature for covered cancers and expect that CMS will consider them in a positive way, Siegel said.
“We hope CMS shares our belief that these data go a long way toward demonstrating that it would be appropriate to cover additional cancers,” he said.
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Study Explores Impact of Insurance on Treatment and Referrals for Patients with Uterine Fibroids
February 19th 2025Women with uterine fibroids and Medicaid coverage are significantly more likely to be treated with uterine artery embolization than those with commercial insurance, according to newly published research.